Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altimmune, Inc.

5.59
-0.1300-2.27%
Post-market: 5.56-0.0300-0.54%19:59 EST
Volume:3.00M
Turnover:16.67M
Market Cap:430.51M
PE:-4.18
High:5.66
Open:5.58
Low:5.41
Close:5.72
Loading ...

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

GlobeNewswire
·
02 Dec 2024

Stock Track | Altimmune Soars 6.69% After-hours on Positive Pembrolizumab Subcutaneous Formulation Phase 3 Data

Stock Track
·
20 Nov 2024

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Business Wire
·
19 Nov 2024

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Business Wire
·
19 Nov 2024

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

GlobeNewswire
·
18 Nov 2024

Executive reshuffles: TWO, CYBR, PFG and ALT

seekingalpha
·
17 Nov 2024

Stock Track | Altimmune (ALT) Plummets 10.64% Despite Positive Phase 1b Data Showing Pemvidutide Reduces Inflammatory Lipids in MASH Patients

Stock Track
·
16 Nov 2024

Altimmune presents data on effect of pemvidutide on inflammatory lipids

TIPRANKS
·
16 Nov 2024

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

GlobeNewswire
·
16 Nov 2024

Altimmune Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
14 Nov 2024

Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Nov 2024

Altimmune call volume above normal and directionally bullish

TIPRANKS
·
14 Nov 2024

Altimmune provided key pipeline updates with Q3 report, says B. Riley

TIPRANKS
·
14 Nov 2024

Altimmune’s pemvidutide looks differentiated among GLP-1s, says H.C. Wainwright

TIPRANKS
·
14 Nov 2024

Altimmune (ALT) Receives a Buy from Evercore ISI

TIPRANKS
·
13 Nov 2024

Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS

Business Wire
·
13 Nov 2024